Again about carbonic anhydrase inhibitors: modern aspects of the use of ICA in ophthalmology

For more than 70 years, the inhibitors of carbonic anhydrase (ICA) have been used in treatment glaucoma. Since 1995, topical forms ICA appeared among antiglaucoma drugs — dorzolamide, and since 1999 brinzolamide. The hypotensive efficacy safety gave rise to widespread use these various peculiarities mechanism action made it possible create on their basis effective fixed combinations, which allow reducing intraocular pressure by up 40 % patients with attractiveness drug has expanded due effect tissues organ vision. Thus, ICAs effectively improve hemodynamics eye optic nerve. antioxidant activity makes expand indications for its vascular patho-logy retina biomechanical characte-ristics allowed safe complex macular edema etiologies. adjuvant expands possibilities anti-VEGF therapy Features endothelial pump function cornea formulate rules an insufficient corneal endothelium.